190 related articles for article (PubMed ID: 31197662)
1. Economic Evaluation of Human Rotavirus Vaccine in Thailand.
Saokaew S; Prasitsuebsai W; Bibera GL; Kengkla K; Zhang XH; Oh KB; Lee C
Infect Dis Ther; 2019 Sep; 8(3):397-415. PubMed ID: 31197662
[TBL] [Abstract][Full Text] [Related]
2. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
3. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
4. Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures.
Botwright S; Win EM; Kapol N; Benjawan S; Teerawattananon Y
Pharmacoeconomics; 2023 Jan; 41(1):77-91. PubMed ID: 36348154
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of childhood rotavirus vaccination in Germany.
Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?
Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y
Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand.
Rochanathimoke O; Riewpaiboon A; Praditsitthikorn N; Tharmaphornpilas P; Jiamsiri S; Thavorncharoensap M; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):811-819. PubMed ID: 34008471
[TBL] [Abstract][Full Text] [Related]
10. Economic Evaluation and Budget Impact Analysis of Vaccination against
Kotirum S; Muangchana C; Techathawat S; Dilokthornsakul P; Wu DB; Chaiyakunapruk N
Front Public Health; 2017; 5():289. PubMed ID: 29209602
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Rotavirus Vaccination in Children Aged Under Five Years in South Africa.
Mohy A; Page N; Boyce W; Gomez JA
Clin Drug Investig; 2023 Nov; 43(11):851-863. PubMed ID: 37831397
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness estimates of vaccination against rotavirus in Piedmont, Italy.
Gualano MR; Thomas R; Gili R; Scaioli G; Voglino G; Zotti C
J Infect Public Health; 2018; 11(6):867-872. PubMed ID: 30078657
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of rotavirus vaccination in children of Bhutan.
Pempa ; Luz ACG; Luangasanatip N; Kingkaew P; Adhikari D; Isaranuwatchai W; Choiphel D; Pecenka C; Debellut F
Vaccine; 2020 Jul; 38(32):5049-5059. PubMed ID: 32522415
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
Villanueva-Uy MET; Lam HY; Aldaba JG; Uy TMZ; Valverde HA; Silva MWT; Mooney J; Clark A; Pecenka C
Vaccine; 2021 Nov; 39(48):7091-7100. PubMed ID: 34753614
[TBL] [Abstract][Full Text] [Related]
15. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
Leelahavarong P; Chaikledkaew U; Hongeng S; Kasemsup V; Lubell Y; Teerawattananon Y
BMC Health Serv Res; 2010 Jul; 10():209. PubMed ID: 20633303
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older.
Shiragami M; Mizukami A; Kaise T; Curran D; Van Oorschot D; Bracke B; Watanabe D
Dermatol Ther (Heidelb); 2019 Jun; 9(2):281-297. PubMed ID: 30929219
[TBL] [Abstract][Full Text] [Related]
17. Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi.
Niyibitegeka F; Thavorncharoensap M; Riewpaiboon A; Youngkong S
Appl Health Econ Health Policy; 2022 Sep; 20(5):707-716. PubMed ID: 35469393
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
Permsuwan U; Thongprasert S; Sirichanchuen B
Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
